Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7396543 | 0.93 | SMN1; SMN2 (0.48) | CYP2D6NPC1RAB9ASMN1; SMN2CACNA1B | |
| SCHEMBL7389597 | 0.89 | FFAR1 (0.54) | CYP2D6NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7400144 | 0.85 | BCHE (0.63) | CYP2D6CACNA1B | |
| SCHEMBL17308276 | 0.84 | KMT2A (0.49) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7390477 | 0.82 | CYP2D6 (0.67) | CYP2D6NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7838776 | 0.82 | MEN1 (0.53) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1229934 | 0.82 | ALDH1A1 (0.53) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12133488 | 0.82 | LTB4R (0.50) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL15587423 | 0.82 | MMP13 (0.47) | CYP2D6SMN1; SMN2CACNA1BTDP1ALDH1A1 | |
| SCHEMBL18672910 | 0.80 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-1990006928-A1 | 6-(1-CARBAMOYL-1-HYDROXYMETHYL)PENICILLANIC ACID DERIVATIVES | BARTH WAYNE E (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4868296-A | 6-(1-carbamoyl-1-hydroxymethyl) penicillanic acid derivatives | PFIZER INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0220939-A1 | 6-(1-Carbamoyl-1-hydroxymethyl)penicillanic-acid derivatives | PFIZER INC. (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | CYP2D6 4576/4885NPC1 1321/4885RAB9A 1139/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | CYP2D6 1899/4885NPC1 746/4885RAB9A 1370/4885 |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | CYP2D6 3901/4885NPC1 2796/4885RAB9A 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.